Atherosclerosis-prone mice transfected with the longevity-associated variant (LAV) of BPIFB4 show reduced endothelial dysfunction and slowed atherogenic plaque progression compared with wild-type controls. These findings, published in the European Heart Journal, indicate that the favourable phenotype associated with long-living individuals and characterized by delayed or absent age-linked, atherosclerosis-related cardiovascular disease can be transferred to animal models via LAV-BPIFB4 gene therapy.
Age is a major risk factor for the development of atherosclerosis. The LAV in BPI fold-containing family B member 4 (BPIFB4) is enriched in long-living individuals and has previously been shown to improve endothelial function when transferred to old mice via gene therapy. In addition, LAV-BPIFB4 is thought to exert immunomodulatory activity, potentially via a CXC-chemokine receptor 4 (CXCR4)-dependent mechanism. “Thus, we adopted a model of atherosclerosis (a potential target of CXCR4 modulators) to evaluate the therapeutic effects of LAV-BPIFB4 in this setting and to determine if this effect was mediated by CXCR4,” comment Carmine Vecchione and Annibale Puca, lead investigators of the study.
LAV-BPIFB4, wild-type-BPIFB4 or an empty vector were delivered via adeno-associated viral transfer into Apoe–/– mice fed a high-fat diet. Mesenteric and femoral arteries taken from Apoe–/– mice overexpressing LAV-BPIFB4 showed diminished endothelial dysfunction compared with wild-type mice. This protective effect was completely abolished by treatment with AMD3100, a non-peptide antagonist of CXCR4. Furthermore, LAV-BPIFB4 gene therapy halted the formation of vascular plaques and reduced macrophage infiltration. These atheroprotective effects were again abolished by co-treatment with AMD3100.
At the immunological level, when autologous macrophages from patients with atherosclerosis were conditioned in vitro with a human recombinant LAV-BPIFB4 protein, the macrophages were polarized towards an anti-inflammatory M2 phenotype in a CXCR4-dependent manner. LAV-BPIFB4 reduced the inflammatory milieu within the vessels and improved endothelial-mediated vasorelaxation.
LAV-BPIFB4 gene therapy halted the formation of vascular plaques and reduced macrophage infiltration
Taken together, these findings demonstrate the efficacy of LAV-BPIFB4 gene therapy in reducing the atherogenic process. “Changes in immunological profile observed after gene therapy with LAV-BPIFB4 makes this approach a potential cure for a broad range of cardiovascular diseases,” concludes Vecchione.
References
Original article
Puca, A. A. et al. Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehz459 (2019)
Further reading
Ferrucci, L. & Fabbri, E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat. Rev. Cardiol. 15, 505–522 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huynh, K. Longevity-associated gene variant halts progression of atherosclerosis. Nat Rev Cardiol 16, 516 (2019). https://doi.org/10.1038/s41569-019-0243-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-019-0243-9